Previous 10 | Next 10 |
Artivion Announces Completion of Enrollment in PERSEVERE Trial PR Newswire ATLANTA , Nov. 9, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enro...
2023-11-05 01:51:09 ET Artivion, Inc. (AORT) Q3 2023 Earnings Conference Call November 2, 2023 04:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Officer Ashley Lee - Executive Vice President and ...
2023-11-02 16:32:34 ET More on Artivion Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025 Historical earnings data for Artivion Financial information for Artivion For further details see: Artivion Non-GAAP EPS of $0.02 mi...
Artivion Reports Third Quarter 2023 Financial Results PR Newswire Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Artivion Inc Com (AORT) is expected to report $0.01 for Q3 2023
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results PR Newswire ATLANTA , Oct. 19, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, ann...
2023-10-13 14:37:09 ET Summary Artivion has used M&A to reposition itself towards growth opportunities in aortic disease care and heart valves. The company's legacy operations contribute positively to revenue and margins but have limited growth prospects. The success of Ar...
Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin PR Newswire Late-Breaking Science Presented at the 37 th European Association for Cardio-Thoracic Surgery Annu...
Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting PR Newswire Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS ATLANTA ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 11:00:15 ET Frank Takkinen from Lake Street issued a price target of $30.00 for AORT on 2024-07-10 09:08:00. The adjusted price target was set to $30.00. At the time of the announcement, AORT was trading at $25.94. The overall price target consensus is at $30....
2024-07-02 12:00:05 ET Frank Takkinen from Loop Capital Markets issued a price target of $30.00 for AORT on 2024-07-02 08:49:00. The adjusted price target was set to $30.00. At the time of the announcement, AORT was trading at $26.015. The overall price target consensus ...